Literature DB >> 10443675

Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity.

A Barlier1, I Pellegrini-Bouiller, G Gunz, A J Zamora, P Jaquet, A Enjalbert.   

Abstract

The impact of the gsp oncogene on the expression of genes engaged in the somatotroph cell phenotype remains poorly understood in human somatotroph adenomas. As the gsp oncogene is associated with an increased octreotide (somatostatin agonist) sensitivity, a group of 8 somatotroph adenomas bearing the gsp mutation (gsp+) and another group of 16 adenomas without the mutation (gsp-) were analyzed, all of them presenting variable octreotide sensitivities. The expressions of genes encoding for G(s)alpha, Pit-1, G(i2)alpha, and SSTR2, involved in the regulation of secretory activity in somatotroph cells, were assessed by Northern blot. A decreased expression of the G(s)alpha gene was found in gsp + tumors, suggesting the existence of a negative feedback of the oncogenic protein upon its own messenger ribonucleic acid (mRNA). In contrast, G(i2)alpha, Pit-1, and GH messengers were not significantly different in the groups. A positive correlation between the in vitro and in vivo GH octreotide-induced secretory inhibition and the expression of SSTR2 mRNA was found. However, the expression of the gene for SSTR2 appeared not to be different between gsp + and gsp-, even when the octreotide sensitivity was significantly higher in the adenomas carrying the mutation. Interestingly, the SSTR2 gene expression was significantly correlated to those of G(i2)alpha and Pit-1. In the same way, the G(s)alpha mRNA expression was positively correlated with those of Gi2alpha and Pit-1. Such correlations strongly suggest a concerted dysregulation of the expression of these genes in both categories of adenomas. The loss of the octreotide sensitivity represents one aspect of the dysregulation process that partially results from the decreased SSTR2 expression. However, the improvement of the sensitivity associated with the presence of the gsp oncogene seems to proceed in a way different from SSTR2 expression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10443675     DOI: 10.1210/jcem.84.8.5919

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Effect of gsp oncogene on somatostatin receptor subtype 1 and 2 mRNA levels in GHRH-responsive GH3 cells.

Authors:  Eunhee Kim; Sookjin Sohn; Mina Lee; Cheolyoung Park; Jeechang Jung; Seungjoon Park
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

2.  Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas.

Authors:  M Filopanti; E Ballarè; A G Lania; S Bondioni; U Verga; M Locatelli; L M Zavanone; M Losa; S Gelmini; A Peri; C Orlando; P Beck-Peccoz; A Spada
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

3.  Unique gene expression profile associated with an early-onset multiple endocrine neoplasia (MEN1)-associated pituitary adenoma.

Authors:  William E Farrell; Monalisa F Azevedo; Dalia L Batista; Alastair Smith; Isabelle Bourdeau; Anelia Horvath; Margaret Boguszewski; Martha Quezado; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2011-09-14       Impact factor: 5.958

4.  Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly.

Authors:  B E Hayward; A Barlier; M Korbonits; A B Grossman; P Jacquet; A Enjalbert; D T Bonthron
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

5.  Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly.

Authors:  Emilie Morin; France Berthelet; John Weisnagel; Martin Bidlingmaier; Omar Serri
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 6.  Genesis of pituitary adenomas: state of the art.

Authors:  G Faglia; A Spada
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

Review 7.  Drug resistance in pituitary tumours: from cell membrane to intracellular signalling.

Authors:  Erika Peverelli; Donatella Treppiedi; Federica Mangili; Rosa Catalano; Anna Spada; Giovanna Mantovani
Journal:  Nat Rev Endocrinol       Date:  2021-06-30       Impact factor: 43.330

8.  Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission.

Authors:  Pamela U Freda; Wendy K Chung; Naoki Matsuoka; Jane E Walsh; M Nabi Kanibir; George Kleinman; Yuanjia Wang; Jeffrey N Bruce; Kalmon D Post
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

9.  G protein mutations in pituitary tumors: a study on Turkish patients.

Authors:  Beki Kan; Christopher Esapa; Tammam Sipahi; Cevdet Nacar; Fahir Ozer; Nur Buyru Sayhan; Mehmet Yaşar Kaynar; Ali Cetin Sarioğlu; Philip Edward Harris
Journal:  Pituitary       Date:  2003-09       Impact factor: 4.107

10.  Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.

Authors:  Ana Paula M Casarini; Raquel S Jallad; Emília M Pinto; Iberê C Soares; Suely Nonogaki; Daniel Giannella-Neto; Nina R Musolino; Venâncio A F Alves; Marcello D Bronstein
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.